Seoul Pharma Co Ltd - ESG Rating & Company Profile powered by AI
This report of Seoul Pharma Co Ltd uses data from across the web as well as from available disclosures by Seoul Pharma Co Ltd. The SDG rating for Seoul Pharma Co Ltd indicates the company's transparency towards the United Nations SDGs. This webpage is a zero-cost ESG report for Seoul Pharma Co Ltd.
Seoul Pharma Co Ltd in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 0.0; made up of an environmental score of 0.0, social score of 0.0 and governance score of 0.0.
0.0
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1967 | Hospira Inc | 0.3 | Low |
1967 | PRA Health Sciences Inc | 0.3 | Low |
1970 | Seoul Pharma Co Ltd | 0.0 | Low |
1970 | CSPC Innovation Pharmaceutical Co Ltd | 0.0 | Low |
1970 | CTC Bio Inc | 0.0 | Low |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Seoul Pharma Co Ltd have an accelerator or VC vehicle to help deliver innovation?
Does Seoul Pharma Co Ltd disclose current and historical energy intensity?
Does Seoul Pharma Co Ltd report the average age of the workforce?
Does Seoul Pharma Co Ltd reference operational or capital allocation in relation to climate change?
Does Seoul Pharma Co Ltd disclose its ethnicity pay gap?
Does Seoul Pharma Co Ltd disclose cybersecurity risks?
Does Seoul Pharma Co Ltd offer flexible work?
Does Seoul Pharma Co Ltd have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Seoul Pharma Co Ltd disclose the number of employees in R&D functions?
Does Seoul Pharma Co Ltd conduct supply chain audits?
Does Seoul Pharma Co Ltd disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Seoul Pharma Co Ltd conduct 360 degree staff reviews?
Does Seoul Pharma Co Ltd disclose the individual responsible for D&I?
Does Seoul Pharma Co Ltd disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Seoul Pharma Co Ltd disclose current and / or historical scope 2 emissions?
Does Seoul Pharma Co Ltd disclose water use targets?
Does Seoul Pharma Co Ltd have careers partnerships with academic institutions?
Did Seoul Pharma Co Ltd have a product recall in the last two years?
Does Seoul Pharma Co Ltd disclose incidents of discrimination?
Does Seoul Pharma Co Ltd allow for Work Councils/Collective Agreements to be formed?
Has Seoul Pharma Co Ltd issued a profit warning in the past 24 months?
Does Seoul Pharma Co Ltd disclose parental leave metrics?
Does Seoul Pharma Co Ltd disclose climate scenario or pathway analysis?
Does Seoul Pharma Co Ltd disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Seoul Pharma Co Ltd disclose the pay ratio of women to men?
Does Seoul Pharma Co Ltd support suppliers with sustainability related research and development?
Does Seoul Pharma Co Ltd disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Seoul Pharma Co Ltd reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Seoul Pharma Co Ltd involved in embryonic stem cell research?
Does Seoul Pharma Co Ltd disclose GHG and Air Emissions intensity?
Does Seoul Pharma Co Ltd disclose its waste policy?
Does Seoul Pharma Co Ltd report according to TCFD requirements?
Does Seoul Pharma Co Ltd disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Seoul Pharma Co Ltd disclose energy use targets?
Does Seoul Pharma Co Ltd disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Seoul Pharma Co Ltd have a policy relating to cyber security?
Have a different question?
Potential Risks for Seoul Pharma Co Ltd
These potential risks are based on the size, segment and geographies of the company.
Seoul Pharma Co., Ltd manufactures and distributes pharmaceutical products in South Korea and internationally. It provides Orally Disintegrating Film (ODF), a thin film that provides an alternative to orally disintegrating tablets with modifications. The company offers ODF products for therapeutic areas, including urology, neurology, nutrition, endocrinology, and OB/GY. Its products include VULTEUM and VULTIS for erectile dysfunction; ARTPEZIL for Alzheimer' disease; OBCARE to treat overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency; and CH.V for collagen, hyaluronic acid, and vitamin C, as well as products for schizophrenia, vitamin B, and fatigue and immunity. The company was founded in 1976 and is headquartered in Seoul, South Korea.